Skip to main content

Table 1 Hemodynamics and cardiovascular autonomic modulation in control (Cont, n = 8), control nicotinamide (Cont+NicA, n = 7), diabetic (Diab, n = 7), and diabetic nicotinamide (Diab+NicA, n = 8) groups

From: Nicotinamide attenuates streptozotocin-induced diabetes complications and increases survival rate in rats: role of autonomic nervous system

 

Cont

Cont + NicA

Diab

Diab + NicA

P value

Heart rate (bpm)

338 ± 6

343 ± 6

255 ± 6*

299 ± 10#

p < 0.05

Mean blood pressure (mmHg)

110 ± 2

115 ± 2

94 ± 3*†

101 ± 2#

p < 0.05

HRV (ms2)

105.1 ± 15.5

101.4 ± 17.6

129.6 ± 28.9

120.9 ± 17.7

p > 0.05

RMSSD (ms)

4.8 ± 0.3

6.7 ± 0.6

5.4 ± 0.2

9.3 ± 1.2*#

p < 0.05

LF (ms2)

4.5 ± 0.7

4.2 ± 1.0

3.6 ± 0.8

5.2 ± 0.7

p > 0.05

HF (ms2)

13.0 ± 0.8

13.8 ± 2.2

7.0 ± 1.2*†

13.7 ± 1.6#

p < 0.05

LF (n.u.)

22.8 ± 2.8

19.8 ± 3.3

25.6 ± 3.7

23.5 ± 2.4

p > 0.05

HF (n.u.)

77.1 ± 2.8

80.1 ± 3.3

71.2 ± 3.7

76.5 ± 2.4

p > 0.05

LF/HF

0.30 ± 0.04

0.30 ± 0.05

0.46 ± 0.04

0.36 ± 0.04

p > 0.05

SAPV (mmHg2)

43.9 ± 1.8

42.2 ± 4.8

21.8 ± 10.0

33.1 ± 3.8

p > 0.05

  1. HRV Heart rate variability; SAPV systolic arterial pressure variability computed from 0.20 to 3 Hz (total power), low-frequency (LF: 0.20–0.75 Hz) and high-frequency (HF: 0.75–3 Hz) bands; RMSSD root mean square of successive differences; n.u normalized units. *p < 0.05 vs. Cont; #p < 0.05 vs. Diab, p < 0.05 vs. Cont+NicA